T-Therapeutics has secured $133 million in a funding round aimed at advancing its bispecific antibody technology. The startup focuses on developing treatments for known, yet undruggable cancer targets, as well as designing selective therapies for autoimmune diseases. This significant investment could enhance T-Therapeutics’ capabilities in targeting challenging disease areas, potentially positioning the company as a key player in the oncology and autoimmune treatment landscape.
Source: biopharmadive.com · Image: Immunology laboratory at the central cancer research labs by Unknown photographer, Public domain, via Wikimedia Commons
Affordable access, full power:
For just $42 per month, the “Solo” plan unlocks the same API & FDF Intelligence data used by global companies.
You instantly see price ranges, dossiers, and certificates — and, most importantly, gain direct contacts to every manufacturer and FDF holder.
It’s a practical way to work with reliable data without heavy budgets.
Get started today with Solo access →
Get started today with Solo access →
